Drug Trial Radar · NCT05835986
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Dec 18, 2023
Primary completion
Nov 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Apr 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7507062 in participants with systemic lupus erythematosus (SLE). The study will have 2 parts: Part 1 is a single ascending dose-finding (SAD) part and Part 2 is a dose escalation with fractionated dosing part.
Conditions
- Systemic Lupus Erythematosus
Interventions
RO7507062Drug
RO7507062 solution for injection will be administered SC as specified in each treatment part (arm).
TocilizumabDrug
When applicable, tocilizumab solution for infusion will be administered intravenously at 8 milligram per kilogram (mg/kg) for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants with Dose Limiting Adverse Events (DLAEs)Time frame: Day 1 through Day 29
- Part 2: Fractionated Dose Cohort: Number of Participants with DLAEsTime frame: Day 1 through to the end of the 28-day safety evaluation period
- Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 12 months
Locations
18 sites in 13 countries. Site status is shown where the registry gives one.
Clinica De La Costa
Barranquilla, Colombia
Hospital Pablo Tobon Uribe
Medellín, Colombia
Groupe Hospitalier Pitie-Salpetriere
Paris, France
Charité Research Organisation GmbH
Berlin, Germany
Hospital Umum Sarawak
Kuching, Malaysia
CREA Hospital Mexico Americano
Guadalajara, Jalisco, Mexico
Hospital Angeles De Lindavista
Mexico City, Mexico CITY (federal District), Mexico
Hospital General De Mexico
Mexico City, Mexico CITY (federal District), Mexico
Centre For Human Drug Research
Leiden, Netherlands
Clínica San Juan Bautista CSJB
Lima, Peru
Wojskowy Instytut Medyczny- Panstwowy Instytut Badawczy
Warsaw, Poland
FARMOVS (Pty) Ltd
Bloemfontein, South Africa
Hospital General Universitario Gregorio Marañon
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Chung Shan Medical University Hospital
Taichung, Taiwan
Chang Gung Medical Foundation - Linkou
Taoyuan, Taiwan
Ramathibodi Hospital, Mahidol Uni
Bangkok, Thailand
UCL Hospital NHS Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.